← Pharmacy curriculum
Module 10410 lessonsNaS synthesis of RxPrep 2023 with current BSR, EULAR, ACR, Sjogren's Foundation, and FDA guidance

Sjogren Disease

Recognize Sjogren disease as a systemic autoimmune disorder, confirm the phenotype with objective testing, protect the ocular and oral surfaces, use secretagogues safely, treat active organ disease deliberately, and investigate lymphoma and pregnancy related risk.

01

Connect immune mediated lacrimal and salivary injury to systemic B cell activation and organ disease.

02

Recognize ocular, oral, neurologic, pulmonary, renal, vascular, hematologic, and constitutional manifestations.

03

Calculate the 2016 ACR EULAR classification score while distinguishing classification from clinical diagnosis.

04

Stage dry eye by mechanism and severity, then sequence lubrication, anti-inflammatory therapy, tear conservation, and advanced ophthalmic care.

05

Build an oral prevention plan that protects teeth, mucosa, swallowing, nutrition, and infection defense.

06

Use pilocarpine and cevimeline with exact dosing, contraindications, monitoring, and response targets.

07

Reserve systemic immunotherapy for active systemic disease rather than treating dryness alone.

08

Recognize lymphoma predictors and new findings that require prompt investigation.

09

Plan anti-SSA and anti-SSB positive pregnancy before conception with coordinated fetal surveillance.

10

Create a longitudinal multidisciplinary plan with explicit reassessment and escalation thresholds.

104.01

Build the Autoimmune Exocrinopathy

Sjogren disease is not a dehydration disorder. Immune mediated gland dysfunction creates dry eye and dry mouth, while B cell activation and systemic inflammation can affect nerves, lungs, kidneys, blood vessels, joints, and hematologic tissues.

What to learn
  • Lacrimal gland
  • Salivary gland
  • Anti-SSA
  • B cell activation
  • Primary and associated disease
Autoimmune architectureGland injury and systemic B cell activity belong to the same disease
01TargetInjure exocrine tissue

Immune activity reduces lacrimal and salivary function and damages protective surfaces.

02SignalRead antibody context

Anti-SSA, biopsy, and objective gland tests support classification but do not replace diagnosis.

03ExtendSearch beyond dryness

Nerves, lungs, kidneys, vessels, joints, and blood can become clinically important targets.

Start with exocrine function

Lacrimal glands sustain the tear film, while major and minor salivary glands lubricate the mouth, protect enamel, buffer acids, support swallowing, and limit infection. Loss of output creates tissue injury as well as discomfort.

Build the immune model

T cells, B cells, autoantibodies, cytokine signaling, epithelial activation, and focal lymphocytic inflammation contribute to disease. Anti-SSA supports classification and pregnancy risk assessment, but no antibody result replaces the clinical phenotype.

Use current terminology

Many current sources use Sjogren disease to emphasize a systemic disorder. It can occur without another autoimmune disease or in association with conditions such as rheumatoid arthritis or systemic lupus erythematosus.

Protect seronegative disease

A negative standard antibody panel does not settle every case. Objective ocular, salivary, pathologic, and systemic findings remain important when clinical probability is high.

Separate cause from consequence

Dryness can also result from anticholinergic medicines, dehydration, diabetes, radiation, infection, environmental exposure, aging, and other diseases. A rigorous evaluation identifies mimics and complications before assigning cause.

0 of 1 answered
01Which statement best frames Sjogren disease?
Answer every question to submit.
104.02

Recognize the Full Clinical Spectrum

Persistent dry eye and dry mouth are central, but a complete assessment also looks for functional loss, tissue damage, systemic activity, and findings that cannot safely wait for routine follow-up.

What to learn
  • Keratoconjunctivitis sicca
  • Xerostomia
  • Fatigue
  • Extraglandular disease
  • Urgent red flags
Clinical spectrumFunction, tissue injury, and systemic change determine urgency
01DescribeMeasure sicca burden

Vision, speech, swallowing, sleep, nutrition, and dental health reveal the real cost of dryness.

02ScreenMap systemic domains

Raynaud, purpura, neuropathy, dyspnea, renal loss, cytopenia, and gland swelling change the plan.

03EscalateName red flags

Eye pain, vision loss, progressive weakness, persistent gland enlargement, and B symptoms cannot wait.

Characterize ocular symptoms

Grittiness, burning, photophobia, fluctuating vision, contact lens intolerance, and reflex tearing can accompany aqueous deficiency. Eye pain, reduced vision, focal epithelial injury, or ulceration requires urgent ophthalmic evaluation.

Characterize oral symptoms

Patients may carry water, wake to drink, struggle with dry food, speak for shorter periods, lose taste, develop oral burning, or experience recurrent caries and candidiasis. Ask how symptoms change nutrition and medicine administration.

Search beyond the glands

Inflammatory joint symptoms, Raynaud phenomenon, purpura, neuropathy, interstitial lung disease, renal tubular disease, cytopenias, thyroid disease, lymphadenopathy, and salivary gland enlargement can occur.

Interpret fatigue carefully

Fatigue can reflect inflammatory disease, pain, poor sleep, depression, anemia, thyroid dysfunction, medicine burden, or another disorder. It deserves a differential diagnosis rather than automatic immunosuppression.

Name urgent findings

Severe eye pain or vision change, inability to maintain intake, rapidly progressive weakness, dyspnea, purpura, persistent gland swelling, unexplained fever, drenching night sweats, and substantial weight loss require prompt escalation.

0 of 1 answered
01Which new finding most strongly requires prompt investigation?
Answer every question to submit.
104.03

Use Objective Tests Without Confusing Their Roles

The 2016 ACR EULAR criteria use five weighted objective findings. They improve consistency for research and support clinical reasoning, but a classification threshold is not a substitute for diagnosis or a reason to ignore early disease.

What to learn
  • Anti-SSA
  • Labial biopsy
  • Ocular staining
  • Schirmer test
  • Unstimulated salivary flow
Weighted classificationFive objective findings contribute different evidence
01Three pointsAnti-SSA or qualifying biopsy

Either finding carries the greatest weight in the 2016 ACR EULAR score.

02One pointMeasure surface and flow

Ocular staining, Schirmer testing, and unstimulated saliva each add one when abnormal.

03InterpretKeep diagnosis clinical

A score of four classifies an eligible patient, but early disease still requires longitudinal judgment.

Calculate the score

Anti-SSA positivity and focal lymphocytic sialadenitis with a focus score of at least one each contribute three points. Ocular staining score at least five, Schirmer at most five millimeters in five minutes, and unstimulated whole saliva flow at most 0.1 milliliters per minute each contribute one point. A total of four classifies an eligible patient.

Check applicability

The criteria apply to patients with compatible dryness or systemic suspicion after relevant exclusions are considered. Head and neck radiation, active hepatitis C, AIDS, sarcoidosis, amyloidosis, graft versus host disease, and IgG4 related disease can interfere with classification.

Distinguish classification from diagnosis

Classification criteria were designed to standardize research populations. A clinician may continue evaluation when probability remains high despite a score below four, especially early in disease.

Use each test for its question

Schirmer testing measures tear production, ocular staining measures surface injury, salivary flow measures gland output, serology identifies immune markers, and labial biopsy can demonstrate focal inflammation. None answers every question alone.

Review reversible interference

Anticholinergic medicines and other sicca causes should be addressed when feasible before testing. Biopsy interpretation requires experienced pathology because focus score and tissue quality matter.

0 of 1 answered
01An eligible patient has anti-SSA positivity and a Schirmer result of 4 mm in five minutes. What is the classification score?
Answer every question to submit.
104.04

Protect the Ocular Surface From the First Visit

Dry eye care begins with mechanism, severity, and tissue protection. Aqueous deficiency can coexist with meibomian gland dysfunction, so lubrication alone is not always a complete plan.

What to learn
  • Aqueous deficiency
  • Meibomian gland dysfunction
  • Preservative free tears
  • Ointment
  • Punctal occlusion
Ocular surfaceProtect the tear film before inflammation becomes structural injury
01ReplaceChoose the lubricant

Frequent use favors preservative free tears, while gels and ointments extend nighttime protection.

02RestoreTreat mixed mechanisms

Aqueous deficiency and meibomian dysfunction may require different but coordinated measures.

03ReferProtect vision

Pain, photophobia, reduced vision, epithelial defect, or ulceration needs urgent ophthalmic care.

Reduce avoidable exposure

Review airflow, smoke, low humidity, prolonged screen use, incomplete blinking, contact lenses, and medicines that worsen dryness. Environmental changes support therapy but do not replace treatment of active surface disease.

Choose lubrication deliberately

Artificial tears are foundational. Preservative free products are preferred when drops are used frequently or preservatives cause irritation. Gels and ointments last longer and are often useful at night but can blur vision.

Treat mixed mechanism disease

Warm compresses, lid hygiene, and targeted management of meibomian gland dysfunction may be needed when evaporative disease accompanies aqueous deficiency.

Conserve tears selectively

Punctal occlusion can retain tears in selected patients. Surface inflammation, infection, tear composition, and the broader treatment plan should be assessed before plugs or cautery are used.

Escalate before sight is threatened

Persistent pain, photophobia, reduced vision, epithelial defect, or corneal ulceration warrants urgent examination. Severe disease may require autologous serum, scleral lenses, or other specialist procedures.

0 of 1 answered
01A patient needs artificial tears eight times daily and reports increasing drop related burning. What is the best next step?
Answer every question to submit.
104.05

Treat Ocular Inflammation on the Correct Timeline

Topical cyclosporine and lifitegrast address inflammatory dry eye rather than providing immediate lubrication. Their value depends on regular use, correct technique, realistic timelines, and severity based ophthalmic follow-up.

What to learn
  • Cyclosporine
  • Lifitegrast
  • LFA-1
  • Delayed benefit
  • Advanced therapy
Anti-inflammatory eye careRegular treatment changes the surface on a slower clock
01CyclosporineReduce ocular inflammation

Delayed benefit and local burning require realistic counseling and sustained use when tolerated.

02LifitegrastBlock LFA-1 signaling

Twice daily dosing, lens separation, dysgeusia, and single dose technique shape safe use.

03AdvanceMatch procedure to severity

Punctal care, serum tears, scleral lenses, and supervised steroids require specialist selection.

Use topical cyclosporine

Cyclosporine reduces ocular surface inflammation and can support tear production in selected patients. Burning can occur, and meaningful benefit may take weeks to months. Some emulsions require gentle inversion before use according to product instructions.

Use lifitegrast

Lifitegrast is an LFA-1 antagonist labeled for signs and symptoms of dry eye. Instill one drop in each eye twice daily about 12 hours apart. Irritation, dysgeusia, and transient visual effects are important counseling points.

Teach device and lens technique

Single dose containers are discarded after use. Contact lenses are removed before lifitegrast and may be reinserted after 15 minutes. Avoid touching the container tip to the eye or another surface.

Use corticosteroids narrowly

A short topical corticosteroid course can be useful in selected inflammatory flares, but intraocular pressure, cataract, infection, and corneal risks require eye specialist supervision. It is not an indefinite self-directed treatment.

Match advanced care to severity

Punctal procedures, autologous serum tears, scleral lenses, amniotic membrane, and other interventions are considered when optimized topical therapy does not adequately protect the ocular surface.

0 of 1 answered
01Which counseling point is correct for lifitegrast?
Answer every question to submit.
104.06

Preserve Teeth, Mucosa, Swallowing, and Nutrition

Saliva protects much more than comfort. A prevention plan begins before the first cavity and integrates fluoride, dental surveillance, salivary support, infection recognition, diet, and medicine review.

What to learn
  • Topical fluoride
  • Xylitol
  • Saliva substitutes
  • Candidiasis
  • Dental prevention
Oral protectionSaliva defends enamel, mucosa, swallowing, and nutrition
01PreventUse topical fluoride

Strong prevention begins before the first cavity and continues with structured dental care.

02SupportStimulate without injury

Water, xylitol, substitutes, and humidification avoid the sugar and acid costs of unsafe strategies.

03InspectFind complications

Caries, erosion, candidiasis, mucosal injury, dysphagia, and poor intake require active care.

Make fluoride foundational

The Sjogren's Foundation strongly recommends topical fluoride for patients with dry mouth. Dental professionals individualize formulation and frequency from caries risk, dentition, and tolerance.

Stimulate safely

Frequent water, sugar free xylitol gum or lozenges, saliva substitutes, and humidification can reduce burden. Avoid using frequent sugar or acidic candy as a salivary strategy because it can accelerate caries and erosion.

Review medicines and products

Anticholinergic medicines, sedating antihistamines, some antidepressants, bladder medicines, tobacco, alcohol, and alcohol containing mouth products can worsen dryness or oral injury. Modify therapy only through coordinated risk benefit decisions.

Look for complications

Inspect for caries, erosion, cracked mucosa, ulcers, denture injury, candidiasis, altered taste, and swallowing difficulty. Oral burning or plaques should not automatically be labeled autoimmune.

Protect intake and administration

Difficulty swallowing dry food can reduce nutrition and adherence. Use moisture, texture modification, dietitian support, and dosage form review rather than crushing medicines without checking whether the formulation permits it.

0 of 1 answered
01Which intervention has the strongest preventive role for Sjogren related dry mouth?
Answer every question to submit.
104.07

Use Systemic Secretagogues as Measured Therapeutic Trials

Pilocarpine and cevimeline can increase exocrine secretion when residual gland function remains, but their systemic muscarinic effects require cardiopulmonary, ocular, gastrointestinal, and medication review.

What to learn
  • Muscarinic agonism
  • Pilocarpine
  • Cevimeline
  • Sweating
  • Bronchospasm
Systemic muscarinic therapyMore secretion is useful only when function improves safely
01PilocarpineDose four times daily

Five milligrams four times daily is the current Sjogren xerostomia regimen.

02CevimelineDose three times daily

Thirty milligrams three times daily can improve saliva with a distinct schedule and tolerability profile.

03MonitorControl cholinergic harm

Sweating, gut effects, breathing, vision, heart rate, and hydration define the usable trial.

Use pilocarpine precisely

Current labeling recommends pilocarpine 5 mg by mouth four times daily for Sjogren related dry mouth. Sweating, flushing, urinary frequency, nausea, diarrhea, dizziness, visual change, bradycardia, and bronchial effects can occur.

Use cevimeline precisely

Cevimeline is labeled at 30 mg by mouth three times daily for Sjogren related dry mouth. It can increase salivation but also sweating, gastrointestinal effects, secretions, airway resistance, heart rate or conduction effects, and miosis.

Respect contraindications

Cevimeline is contraindicated in uncontrolled asthma, known hypersensitivity, and when miosis is undesirable, including acute iritis and angle closure glaucoma. Pilocarpine has parallel concern for uncontrolled asthma and conditions where miosis is undesirable.

Use caution beyond the label headline

Significant cardiovascular disease, controlled pulmonary disease, gallbladder or biliary disease, kidney stones, and medicines that alter cholinergic function or heart rate may require closer review.

Define trial success

Choose a functional target such as easier speech, safer swallowing of dry food, fewer nighttime awakenings, or improved oral comfort. Reassess response, sweating, hydration, hemodynamics, vision, breathing, and adherence rather than continuing an ineffective drug indefinitely.

0 of 1 answered
01Which patient should not start cevimeline without resolving a major contraindication?
Answer every question to submit.
104.08

Treat Active Organ Disease, Not Dryness by Default

Systemic treatment is organized around the affected organ, severity, reversibility, and risk. Topical care remains central for dryness, while glucocorticoids, conventional immunosuppressants, and biologics are reserved for selected systemic disease.

What to learn
  • ESSDAI
  • Hydroxychloroquine
  • Glucocorticoids
  • Immunosuppressants
  • Rituximab
Organ directed therapyThe inflammatory target must be named before immune risk is accepted
01SeparateDo not immunosuppress dryness

Topical and secretory care remain the foundation for glandular symptoms.

02SelectTreat the active organ

Hydroxychloroquine, glucocorticoids, conventional therapy, and biologics have different roles.

03MeasureTrack response and harm

Disease activity, function, infection, organ toxicity, and steroid burden define success.

Separate glandular and systemic goals

Artificial tears, oral prevention, and secretagogues treat glandular manifestations. Broad immunosuppression has not shown consistent value for dryness alone and should not substitute for surface protection.

Use hydroxychloroquine selectively

Hydroxychloroquine may be considered in selected inflammatory musculoskeletal or systemic contexts. It is not a dependable treatment for isolated dryness or fatigue, and standard retinal, interaction, and dose safety still apply.

Use glucocorticoids cautiously

When active systemic disease requires glucocorticoids, use the minimum effective exposure and develop a taper or steroid sparing strategy. Infection, bone, metabolic, ocular, cardiovascular, and adrenal harms remain important.

Match immune therapy to the organ

Conventional immunosuppressants and biologics are selected for manifestations such as vasculitis, significant lung disease, renal disease, inflammatory neurologic disease, or hematologic complications. Evidence and choice differ across organs.

Use biologics for selected severe disease

Rituximab and other targeted approaches may be considered for severe refractory systemic disease in specialist care, especially where B cell driven pathology is prominent. They are not routine therapy for uncomplicated sicca.

0 of 1 answered
01A patient has stable sicca symptoms without inflammatory organ disease and requests rituximab solely for dryness. What is the best response?
Answer every question to submit.
104.09

Build Lymphoma Surveillance Into Routine Care

Sjogren disease carries a clinically important lymphoma risk. Surveillance is not indiscriminate scanning; it is disciplined attention to gland, node, spleen, skin, constitutional, laboratory, and disease activity changes.

What to learn
  • Parotid enlargement
  • Low C4
  • Cryoglobulins
  • Monoclonal gammopathy
  • B symptoms
Lymphoma surveillancePersistent change matters more than routine scanning
01ObserveFind gland and node change

Persistent parotid enlargement, lymphadenopathy, splenomegaly, and purpura increase concern.

02CorrelateRead laboratory risk

Low complement, cryoglobulins, cytopenias, and monoclonal patterns sharpen the signal.

03InvestigateAct on B symptoms

Fever, drenching night sweats, and substantial weight loss need prompt evaluation.

Recognize clinical predictors

Persistent salivary gland enlargement, lymphadenopathy, splenomegaly, palpable purpura, peripheral neuropathy, and high systemic disease activity increase concern, especially when patterns change.

Recognize laboratory predictors

Low complement, cryoglobulinemia, lymphopenia or other cytopenias, hypergammaglobulinemia, rheumatoid factor, monoclonal gammopathy, and clonal lymphocytosis can strengthen concern in context.

Separate B symptoms from chronic fatigue

Unexplained fever, drenching night sweats, and substantial unintended weight loss are not routine fatigue. Infection, malignancy, and active systemic disease require evaluation.

Investigate the change

The workup is directed by the finding and may include examination, blood counts, chemistry, complement, protein studies, imaging, ultrasound, flow cytometry, or tissue diagnosis through rheumatology, hematology, radiology, and pathology.

Avoid false reassurance

Routine symptoms may fluctuate, but persistent unilateral gland enlargement, hard or fixed nodes, progressive cytopenia, or a new monoclonal pattern requires an explicit plan rather than watchful silence.

0 of 1 answered
01Which combination most strongly raises lymphoma concern?
Answer every question to submit.
104.10

Coordinate Longitudinal Care and Pregnancy Before Risk Appears

Effective care connects rheumatology, ophthalmology, dental or oral medicine, primary care, pharmacy, and relevant organ specialists. Pregnancy, new organ symptoms, and treatment changes are planned rather than handled after complications emerge.

What to learn
  • Anti-SSA pregnancy
  • Fetal surveillance
  • Medication review
  • Multidisciplinary care
  • Reassessment
Longitudinal systemOcular, oral, systemic, reproductive, and safety plans move together
01CoordinateConnect the care team

Rheumatology, eye, dental, primary, pharmacy, and organ specialists share one plan.

02PlanPrepare pregnancy early

Anti-SSA and anti-SSB status changes medicine review and fetal surveillance.

03ReturnUse explicit thresholds

Vision, intake, breathing, neurologic, glandular, constitutional, and toxicity changes trigger earlier care.

Plan pregnancy early

Anti-SSA with or without anti-SSB can cause neonatal lupus and fetal conduction disease. Preconception counseling aligns disease control, pregnancy compatible medicines, antibody status, and maternal fetal medicine involvement.

Use guideline based surveillance

Current ACR guidance conditionally supports serial fetal echocardiography from weeks 16 through 26 for anti-SSA or anti-SSB positive pregnancies, with closer weekly surveillance after a prior affected infant. Hydroxychloroquine is conditionally recommended in antibody positive pregnancy unless contraindicated.

Review medicines as a system

Prescription, OTC, supplement, ocular, oral, and dental products all matter. Anticholinergic burden can worsen dryness, while immunotherapy, pregnancy, infection, organ function, and vaccine plans can alter safety.

Measure the disease domains

Follow symptom function, ocular staining and complications when indicated, dental injury, salivary function, nutrition, lung and neurologic symptoms, kidney and blood abnormalities, gland or node changes, and patient priorities.

Give a return plan

Earlier assessment is needed for vision change, severe eye pain, inability to eat or drink, new dyspnea, neurologic deficit, purpura, persistent gland swelling, fever, night sweats, weight loss, or medication toxicity.

0 of 1 answered
01What is the best next step for an anti-SSA positive patient planning pregnancy?
Answer every question to submit.

Check the connections.

Each attempt draws 10 questions from the complete 112 question bank.

112 questions in this module bank10 questions per attempt

Each attempt draws a fresh set and rearranges the answer choices.

Current clinical foundation.

Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.

  1. British Society for Rheumatology Guideline on Sjogren Disease, 2024
  2. EULAR Recommendations for Sjogren Syndrome Management
  3. 2016 ACR EULAR Classification Criteria
  4. Sjogren's Foundation Clinical Practice Guidelines
  5. ACR Reproductive Health Guideline
  6. DailyMed, Pilocarpine Hydrochloride
  7. DailyMed, Cevimeline Hydrochloride
  8. DailyMed, Lifitegrast Ophthalmic Solution
PharmacyOpen tools